Last reviewed · How we verify
Generic = Plerixafor
Plerixafor is a CXCR4 chemokine receptor antagonist that mobilizes hematopoietic stem cells from the bone marrow into peripheral blood.
Plerixafor is a CXCR4 chemokine receptor antagonist that mobilizes hematopoietic stem cells from the bone marrow into peripheral blood. Used for Mobilization of hematopoietic stem cells to peripheral blood for collection and autologous transplantation in patients with non-Hodgkin lymphoma or multiple myeloma.
At a glance
| Generic name | Generic = Plerixafor |
|---|---|
| Sponsor | Genzyme, a Sanofi Company |
| Drug class | CXCR4 antagonist |
| Target | CXCR4 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Plerixafor blocks the CXCR4 receptor on the surface of hematopoietic stem and progenitor cells, disrupting their interaction with stromal cell-derived factor-1 (SDF-1) in the bone marrow microenvironment. This disruption causes stem cells to be released into the peripheral circulation, where they can be collected for transplantation or mobilized for therapeutic purposes. The drug is used as a mobilizing agent to enhance stem cell collection in patients undergoing autologous stem cell transplantation.
Approved indications
- Mobilization of hematopoietic stem cells to peripheral blood for collection and autologous transplantation in patients with non-Hodgkin lymphoma or multiple myeloma
Common side effects
- Injection site reactions
- Diarrhea
- Nausea
- Fatigue
- Headache
Key clinical trials
- Generic Plerixafor Efficacy of Autologous Hematopoietic Stem Cell Transplantation (PHASE1)
- A Multi-centre, Open Label, Single-arm Study Intended to Further Investigate the Safety and Efficacy of Plerixafor as a Front-line Mobilisation Agent in Combination With G-CSF in Patients With Lymphoma or MM (Multiple Myeloma). (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Generic = Plerixafor CI brief — competitive landscape report
- Generic = Plerixafor updates RSS · CI watch RSS
- Genzyme, a Sanofi Company portfolio CI